MEDVi
Featured PartnerDirect-to-consumer telehealth platform selling compounded GLP-1 weight-loss medications and a compounded sublingual ED product, backed by a 40-year pharmacy partner.
What we like
What to watch
Full Review
MEDVi has carved out a strong position in the compounded GLP-1 market by combining competitive introductory pricing ($179/mo semaglutide) with a no-contract model. The partnership with Belmar Pharma Solutions — an FDA-registered compounding pharmacy with 40+ years of operation — provides meaningful supply-chain credibility. The company's expansion into men's ED via the QUAD sublingual product demonstrates ambitions beyond weight loss. Multiple medication formats (injectable and oral for both semaglutide and tirzepatide) give patients flexibility that many competitors lack.
Last researched: 2026-03-30
Pricing
Prices shown are based on our most recent research and may not reflect current pricing. Telehealth providers update their pricing frequently. Always verify pricing directly with the provider before purchasing.
| Treatment | Category | Price/mo | Includes | Notes |
|---|---|---|---|---|
| Compounded Semaglutide (Injectable) | Weight Loss / GLP-1 | $179–$299 | ● Consults○ Lab work● Shipping | $179 first month No subscription needed |
| Compounded Semaglutide (Oral) | Weight Loss / GLP-1 | $249–$369 | ● Consults○ Lab work● Shipping | $249 first month No subscription needed |
| Compounded Tirzepatide (Injectable) | Weight Loss / GLP-1 | $279–$499 | ● Consults○ Lab work● Shipping | $279 first month No subscription needed |
| MEDVi QUAD (4-in-1 ED Sublingual) | Weight Loss / GLP-1 | $119–$199 | ● Consults○ Lab work● Shipping | No subscription needed |